Role of apoCs in lipoprotein metabolism: Functional differences between ApoC1, ApoC2, and ApoC3

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 3, 1999, Pages 472-484

  Jong, Miek C ^a   Hofker, Marten H ^b   Havekes, Louis M ^c  

^a TNO   (Netherlands)

^b MGC Department of Human Genetics   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Apolipoproteins; Lipoprotein lipase; Lipoproteins, VLDL; Mice, transgenic; Triglycerides

Indexed keywords

APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; LIPOPROTEIN; LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; GENE OVEREXPRESSION; GENETIC DISORDER; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 0033015655     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.3.472     Document Type: Article

References (180)

1. Davison PJ, Norton P, Wallis SC, Gill L, Cook M., Williamson R, Humphries SR. There are two gene sequences for human apolipoprotein C1 (APO C1) on chromosome 19, one of which is 4 kb from the gene for apoE. Biochem Biophys Res Commun. 1986;136:876-884.
2. Myklebost O, Rogne S. The gene for human apolipoprotein C1 is located 4.3 kilobases away from the apolipoprotein E gene on chromosome 19. Hum Genet. 1986;73:286-289.
3. Smit M, van der Kooij-Meijs E, Frants RR, Havekes LM, Klasen EC. Apolipoprotein gene cluster on chromosome 19: definite localization of the APOC2 gene and the polymorphic HpaI site associated with type III hyperlipoproteinemia. Hum Genet. 1988;78:90-93.
4. Lauer S, Walker D, Elshourbagy NA, Reardon CA, Levy-Wilson B, Taylor JM. Two copies of the human apolipoprotein C-I gene are linked closely to the apolipoprotein E gene. J Biol Chem. 1988;263:7277-7286.
5. Li W-H, Tanimura M, Luo C-C, Datta S, Chan L. The apolipoprotein multigene family: biosynthesis, structure, structure-function relationships, and evolution. J Lipid Res. 1988;29:245-271.
6. Myklebost O, Williamson B, Markham AF, Myklebost SR, Rogers J, Woods DE, Humphries SE. The isolation and characterization of cDNA clones for human apolipoprotein CII. J Biol Chem. 1984;259: 4401-4404.
7. Wei C-F, Tsao Y-K, Robberson DL, Gotto AM Jr, Brown K, Chan L. The structure of the human apolipoprotein C-II gene. J Biol Chem. 1985;260:15211-15221.
8. Das HK, Jackson CL, Miller DA, Leff T, Breslow JL. The human apolipoprotein C-II gene sequence contains a novel chromosome 19-specific minisatellite in its third intron. J Biol Chem. 1987;262: 4787-4793.
9. van Eck MM, Hoffer MJV, Havekes LM, Frants RR, Hofker MH. The apolipoprotein C2-linked (AcI) gene: a new gene within the mouse apolipoprotein e-cl-c2 gene cluster. Genomics. 1994;21:110-115.
10. Allan CM, Walker D, Segrest JP, Taylor JM. Identification and characterization of a new human gene (APOC4) in the apolipoprotein E, C-I, and C-II gene locus. Genomics. 1995;28:291-300.
11. Taylor JM, Simonet WS, Bucay N, Lauer SJ, de Silva HV. Expression of the human apolipoprotein E/apolipoprotein C-I locus in transgenic mice. Curr Opin Lipidol. 1991;2:73-80.
12. Zannis VI, Kardassis D, Cardot P, Hadzopoulou-Cladaras M, Zanni EE, Cladaras C. Molecular biology of the human apolipoprotein genes: gene regulation and structure/function relationship. Curr Opin Lipidol. 1992; 3:96-113.
13. Shachter NS, Zhu Y, Walsh A, Breslow JL, Smith JD. Localization of a liver-specific enhancer in the apolipoprotein E/C-I/C-II gene locus. J Lipid Res. 1993;34:1699-1707.
14. Simonet WS, Bucay N, Lauer SJ, Taylor JM. A far-downstream hepatocyte-specific control region directs expression of the linked human apolipoprotein E and C-I genes in transgenic mice. J Biol Chem. 1993; 268:8221-8229.
15. Allan CM, Walker D, Taylor JM. Evolutionary duplication of a hepatic control region in the human apolipoprotein E locus: identification of a second region that confers high level and liver-specific expression of the human apolipoprotein E gene in transgenic mice. J Biol Chem. 1995; 270:26278-26281.
16. Allan CM, Taylor S, Taylor JM. Two hepatic enhancers, HCR.1 and HCR.2, coordinate the liver expression of the entire human apolipoprotein E/C-I/C-IV/CII gene cluster. J Biol Chem. 1997;272: 29113-29119.
17. Karathanasis SK. Apolipoprotein multigene family: tandem organization of human apolipoprotein AI, CIII, and AIV genes. Proc Natl Acad Sci U S A. 1985;82:6374-6378.
18. Protter AA, Levy-Wilson B, Miller J, Bencen G, White T, Seilhamer JJ. Isolation and sequence analysis of the human apolipoprotein CIII gene and the intergenic region between the apo AI and apo CIII genes. DNA. 1984;3:449-456.
19. Elshourbagy NA, Walker DN, Boguski MS, Gordon JI, Taylor JM. The nucleotide and derived amino acid sequence of human apolipoprotein A-IV mRNA and the close linkage of its gene to the genes of apolipoproteins A-I and C-III. J Biol Chem. 1986;261:1998-2002.
20. Sharpe CR, Sidoli A, Shelley CS, Lucero MA, Shoulders CC, Baralle FE. Human apolipoproteins AI, AII, CII and CIII, cDNA sequences and mRNA abundance. Nucleic Acids Res. 1984;12:3917-3932.
21. Karathanasis SK, Zannis VI, Breslow JL. Isolation and characterization of cDNA clones corresponding to two different human apoC-III alleles. J Lipid Res. 1985;26:451-456.
22. Cheung P, Kao FT, Law ML, Jones C, Puck TT, Chan L. Localization of the structural gene for human apolipoprotein A-I on the long arm of human chromosome 11. Proc Natl Acad Sci U S A. 1984;81:508-511.
23. Zannis VI, Cole SF, Jackson C, Kurnit DM, Karathanasis SK. Distri-bution of apolipoprotein A-I, C-II, C-III, and E mRNA in fetal human tissues: time-dependent induction of apolipoprotein mRNA by cultures of human monocyte-macrophages. Biochemistry. 1985;24:4450-4455.
24. Reue K, Leff T, Breslow JL. Human apolipoprotein CIII gene expression is regulated by positive and negative cis-acting elements and tissue specific protein factors. J Biol Chem. 1988;263:6857-6864.
25. Ogami K, Hadzopoulou-Cladaras M, Cladaras C, Zannis VJ. Promoter elements and factors required for hepatic and intestinal transcription of the human apoCIII gene. J Biol Chem. 1990;265:9808-9815.
26. Omori K, Vergnes L, Zakin MM, Ochoa A. The apolipoprotein AI-CIII-AIV gene cluster: sequence of the apoCIII-apoAIV intergenic region. Gene. 1995;159:231-234.
27. Vergnes L, Taniguchi T, Omori K, Zakin MM, Ochoa A. The apolipoprotein A-I/C-III/A-IV gene cluster: apoC-III and apoA-IV expression is regulated by two common enhancers. Biochim Biophys Acta. 1997;1348:299-310.
28. Lauer SJ, Simonet WS, Bucay N, de Silva HV, Taylor JM. Tissue-specific expression of the human apolipoprotein A-IV gene in transgenic mice. Circulation. 1991;84(suppl II):II-17. Abstract.
29. Walsh AM, Azrolan N, Wang K, Marcigliano A, O'Connell A, Breslow JL. Intestinal expression of the human apoA-I gene in transgenic mice is controlled by a DNA region 3′ to the gene in the promoter of the adjacent convergently transcribed apoC-III gene. J Lipid Res. 1993;34: 617-623.
30. Dumon MF, Clerc M. Preliminary report on a case of apolipoprotein CI and CII deficiency. Clin Chim Acta. 1986;157:239-248.
31. Glomset JA, Janssen ET, Kennedy R, Dobbins J. Role of plasma lecithin:holesterol acyltransferase in the metabolism of high density lipoproteins. J Lipid Res. 1966;7:638-648.
32. Breckenridge WC, Little JA, Steiner G, Chow A, Poapst M. Hypertriglyceridemia associated with deficiency of apolipoprotein CII. N Engl J Med. 1978;298:1265-1273.
33. Cox DW, Breckenridge WC, Little JA. Inheritance of apolipoprotein C-II deficiency with hypertriglyceridemia and pancreatitis. N Engl J Med. 1978;299:1421-1424.
34. Wang CS. Structure and functional properties of apolipoprotein C-II. Prog Lipid Res. 1991;30:253-258.
35. Santamarina-Fojo S. Genetic dyslipoproteinemias: role of lipoprotein lipase and apolipoprotein C-II. Curr Opin Lipidol. 1992;3:186-195.
36. Fojo SS, Brewer HB Jr. Hypertriglyceridaemia due to genetic defects in lipoprotein lipase and apolipoprotein C-II. J Intern Med. 1992;231: 669-677.
37. Nijmegen) of a patient with a deficiency of apolipoprotein C-II. J Biol Chem. 1988;263: 17913-17916.
38. paris2: a premature termination mutation in the signal peptide of apoC-II resulting in familial chylomicronemia syndrome. J Lipid Res. 1992;33: 361-367.
39. Xiong W, Li W-H, Posner I, Yamamura T, Yamamoto A, Gotto AM Jr, Chan L. No severe bottleneck during human evolution: evidence from two apolipoprotein C-II deficiency alleles. Am J Hum Genet. 1991;48: 383-389.
40. Padova gene in a patient with apolipoprotein C-II deficiency. J Clin Invest. 1989;84:1215-1219.
41. Bari). Biochem Biophys Res Commun. 1990;168:1118-1127.
42. Hamburg) of a patient with Apo C-II deficiency. J Clin Invest. 1988;82:1489-1494.
43. +1 to C mutation in a donor splice site of intron 2 in the apolipoprotein (apo) C-II gene in a patient with apo C-II deficiency: a possible interaction between apo C-II deficiency and apo E4 in a severely hypertriglyceridemic patient. Atherosclerosis. 1997;130:153-160.
44. Paris) of a patient with a deficiency of apolipoprotein C-II. J Biol Chem. 1989;264:20839-20842.
45. Toronto, a nonfunctional human apolipoprotein. Proc Natl Acad Sci U S A. 1987;84:270-273.
46. St. Michael: familial apolipoprotein CII deficiency associated with premature vascular disease. J Clin Invest. 1987;80:1597-1606.
47. Inadera H, Hibino A, Kobayashi J, Kanzaki T, Shirai K, Yukawa S, Saito Y, Yoshida S. A missense mutation (Tip 26→Arg) in exon 3 of the apolipoprotein CII gene in a patient with apolipoprotein CII deficiency (apo CH-Wakayama). Biochem Biophys Res Commun. 1993;193: 1174-1183.
48. Pullinger CR, Zysow BR, Hennessy LK, Frost PH, Malloy MJ, Kane JP. Molecular cloning and characteristics of a new apolipoprotein C-II mutant identified in three unrelated individuals with hypercholesterolemia and hypertriglyceridemia. Hum Mol Genet. 1993;2:69-74.
49. Huff MW, Evans AJ, Wolfe BM, Connelly PW, Maguire GF, Strong WL. Identification and metabolic characteristics of an apolipoprotein C-II variant isolated from a hypertriglyceridemic subject. J Lipid Res. 1990;31:385-396.
50. Hegele RA, Connelly PW, Maguire GF, Huff MW, Leiter L, Wolfe BM, Evans AJ, Little JA. An apolipoprotein CII mutation. CIILys19→Thr identified in patients with hyperlipidemia. Dis Markers. 1991;9:73-80.
51. Zysow BR, Pullinger CR, Hennessy LK, Farese RV, Ghassemzadeh J, Kane JP. The apolipoprotein C-II variant apoC-IILys19→Thr is not associated with dyslipidemia in affected kindred. Clin Genet. 1994;45: 292-297.
52. Carlson LA, Ballantyne D. Changing relative proportions of apolipoproteins CII and CIII of very low density lipoproteins in hypertriglyceridaemia. Atherosclerosis. 1976;23:563-568.
53. Schonfeld G, George PK, Miller J, Reilly P, Witztum J. Apolipoprotein C-II and C-III levels in hyperlipoproteinemia. Metabolism. 1979;28: 1001-1010.
54. Malmendier CL, Lontie JF, Delcroix C, Dubois DY, Magot T, De Roy L. Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients: effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration. Atherosclerosis. 1989;77: 139-149.
55. Le N-A, Gibson JC, Ginsberg HN. Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins. J Lipid Res. 1988;29:669-677.
56. Jabs H-U, Assmann G. Characterization of an apolipoprotein C-III mutant by high performance liquid chromatography and time-of-flight secondary ion mass spectrometry. J Chromatogr. 1987;414:323-333.
57. Maeda H, Uzawa H, Kamei R. Unusual familial apolipoprotein C-III associated with apolipoprotein C-III-0 preponderance. Biochim Biophys Acta. 1981;665:578-585.
58. Maeda H, Hashimoto R, Ogura T, Hiraga S, Uzawa H. Molecular cloning of a human apoC-III variant: Thr 74→ Ala 74 mutation prevents O-glycosylation. J Lipid Res. 1987;28:1405-1409.
59. Roghani A, Zannis VI. Mutagenesis of the glycosylation site of human apoC-III: O-linked glycosylation is not required for apoC-III secretion and lipid binding. J Biol Chem. 1988;263:17925-17932.
60. 58 → Glu): identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia. J Clin Invest. 1991;87:1724-1731.
61. Luttmann S, von Eckardstein A, Wei W, Funke H, Köhler E, Mahley RW, Assmann G. Electrophoretic screening for genetic variation in apolipoprotein C-III: identification of a novel apoC-III variant, apoC-III (Asp45→Asn) in a Turkish patient. J Lipid Res. 1994;35:1431-1440.
62. Pullinger CR, Malloy MJ, Shahidi AK, Ghassemzadeh M, Duchateau P, Villagomez J, Allaart J, Kane JP. A novel apolipoprotein C-III variant, apoC-III (Gln38→Lys), associated with moderate hypertriglyceridemia in a large kindred of Mexican origin. J Lipid Res. 1997;38:1833-1840.
63. Norum NA, Lakier JB, Goldstein S, Angel A, Goldberg RB, Block WD, Noffze DK, Dolphin PJ, Edelglass J, Bogorad DD, Alaupovic P. Familial deficiency in apolipoprotein A-I and C-III and precocious coronary heart disease. N Engl J Med. 1982;306:1513-1519.
64. Schaefer EJ, Ordovas J, Law S, Ghiselli G, Kashyap L, Srivastava L, Heaton WH, Albers J, Connor W, Lindgren F. Familial apolipoprotein A-I and C-III deficiency: variant II. J Lipid Res. 1985;26:1089-1101.
65. Ginsberg HN, Le NA, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson P, Norum R, Brown WV. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI: evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest. 1986;78:1287-1295.
66. Klasen EC, Talmud PJ, Havekes L, de Wit E, van der Kooij-Meijs E, Smit M, Hansson G, Humphries SE. A common restriction fragment length polymorphism of the human apolipoprotein E gene and its relationship to type III hyperlipoproteinemia. Hum Genet. 1987;75: 244-247.
67. Smit M, van der Kooij-Meijs E, Woudt LP, Havekes LM, Frants RR. Exact localization of the familial dysbetalipoproteinemia associated HpaI restriction site in the promoter region of the APOC1 gene. Biochem Biophys Res Commun. 1988;152:1282-1288.
68. Xu Y, Leff T, Shachter N. A common polymorphism in the apoC1 promoter significantly increases apoC1 gene expression. Circulation. 1996;94(suppl I):I-274. Abstract.
69. Rees A, Stocks J, Sharpe CR, Vella MA, Shoulders CC, Katz J, Jowet NI, Baralle FE, Galton DJ. Deoxyribonucleic acid polymorphism in the apolipoprotein A-I-CIII gene cluster: association with hypertriglyceridemia. J Clin Invest. 1985;76:1090-1095.
70. Aalto-Setälä K, Kontula K, Sane T, Nieminen M, Nikki E. DNA polymorphisms of apolipoprotein A-I/C-II and insulin genes in familial hypertriglyceridemia and coronary heart disease. Atherosclerosis. 1987; 66:145-152.
71. Tass S. Strong association of a single nucleotide substitution in the 3′-untranslated region of the apolipoprotein C-III gene with common hypertriglyceridemia in Arabs. Clin Chem. 1989;35:256-259.
72. Ahn YL, Valdez R, Reddy AP, Cole SA, Weiss KM, Ferrell RE. DNA polymorphisms of the apolipoprotein AI/CIII/AIV gene cluster influence plasma cholesterol and triglyceride levels in the Mayans of the Yucatan Peninsula, Mexico. Hum Hered. 1991;41:281-289.
73. Zheng Q, Dammerman M, Takada Y, Matsunaga A, Breslow JL, Sasaki J. An apolipoprotein CIII marker associated with hypertriglyceridemia in Caucasians also confers increased risk in a west Japanese population. Hum Genet. 1994;95:371-375.
74. Ordovas JM, Civeira F, Genest J Jr, Graig S, Robbins AH, Meade T, Pocovi M, Frossard PM, Masharani U, Wilson PWF, Salem DN, Ward RH, Schaefer EJ. Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III, A-IV gene locus: relationships with lipids, apolipoproteins and premature coronary artery disease. Atherosclerosis. 1991;87:75-86.
75. Shoulders CC, Ball MJ, Baralle FE. Genetic marker in apolipoprotein A1/CIII gene complex associated with hypercholesterolemia. Lancet. 1986;ii:1286-1288.
76. Shoulders CC, Ball MJ, Baralle FE. Variation of the apoA1/CIII/AIV gene complex: its association with hyperlipidaemia. Atherosclerosis. 1989;80:111-118.
77. Henderson HE, Landon SV, Michie J, Berger MB. Association of a DNA polymorphism in the apolipoprotein CIII gene with diverse hyperlipidaemic phenotypes. Hum Genet. 1987;75:62-65.
78. Hong SH, Park WH, Lee CC, Song JH, Kim JQ. Association between genetic variations of apoAI-CIII-AIV cluster gene and hypertriglyceridemic subjects. Clin Chem. 1997;43:13-17.
79. Dammerman M, Sandkuijl LA, Halaas JL, Chung W, Breslow JL. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci U S A. 1993;90:4562-4566.
80. Helio T, Paliotie A, Sane T, Tikkanen MJ, Kontula K. No evidence for linkage between familial hypertriglyceridemia and apolipoprotein B, apolipoprotein C-III or lipoprotein lipase genes. Hum Genet. 1994;94: 271-278.
81. Paul-Hayase H, Rosseneu M, Robinson D, Biervliet JPV, Deslypere JP, Humphries SE. Polymorphisms in the apolipoprotein A-I/C-III/AIV gene cluster: detection of genetic variation determining plasma apoA-I, apoC-III and apoA-IV concentrations. Hum Genet. 1992;88:439-446.
82. Shoulders CC, Harry PJ, Lagrost L, White SE, Shah NF, North JD, Gilligan M, Gambert P, Ball MJ. Variation at the apoA1/CIII/AIV gene complex is associated with elevated plasma levels of apoCIII. Atherosclerosis. 1991;87:239-247.
83. Xu CF, Talmud P, Humphries S. Three new polymorphisms of the apoAI-CIII-AIV gene cluster. Mol Cell Probes. 1994;8:331-332.
84. Talmud PJ, Humphries SE. Apolipoprotein C-III gene variation and dyslipidaemia. Curr Opin Lipidol. 1997;8:154-158.
85. Kessling AM, Berg J, Mockleby E, Humphries SE. DNA polymorphisms around the apo AI gene in normal and hyperlipidaemic individuals selected for a twin study. Clin Genet. 1986;29:485-490.
86. Ordovas JM, Schaefer EJ, Salem D, Ward RH, Glueck CJ, Vergani C, Wilson PW, Karathanasis SK. Apolipoprotein A-I gene polymorphism associated with premature coronary artery disease and familial hypoalphalipoproteinemia. N Engl J Med. 1986;314:671-677.
87. Wojciechowski AP, Farall M, Cullen P, Wilson TME, Bayliss JD, Griffin BA, Caslake MD, Packard CJ, Sheperd J, Thakker R, Scott J. Familial combined hyperlipidemia linked to the apolipoprotein A-I/C-III/A-IV gene cluster on chromosome 11q23-q24. Nature. 1991;349: 161-164.
88. Wijsman EM, Motulsky AG, Guo SW, Yang M, Austin MA, Brunzell JD, Deeb S. Evidence against linkage of familial combined hyperlipidemia to the apoAI-CIII-AIV gene complex. Circulation. 1992;86(suppl I):I-420. Abstract.
89. Marcil M, Boucher B, Gagné E, Davignon J, Hayden M, Genest J Jr. Lack of association of the apolipoprotein A-I-CIII-A-IV gene XmnI and SstI polymorphisms and of the lipoprotein lipase gene mutations in familial combined hyperlipoproteinemia in French Canadian subjects. J Lipid Res. 1996;37:309-319.
90. Conner JA, Coates PM, Bennet MJ, Cryer DR, Le N-A. Familial combined hyperlipidemia: use of stable isotopes to demonstrate overproduction of very low density apolipoprotein B by the liver. J Inherited Metab Dis. 1991;14:915-922.
91. Venkatesan S, Cullen P, Pacy P, Halliday D, Scott J. Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arterioscler Thromb. 1993;13:1110-1118.
92. Chait A, Albers JJ, Brunzell JD. Very low density lipoprotein overproduction in genetic forms of hypertriglyceridemia. Eur J Clin Invest. 1980;110:12-22.
93. Dallinga-Thie GM, Bu X-D, van Linde-Sibenius Trip M, Rotter JI, Lusis AJ, de Bruin TWA. Apolipoprotein A-I/C-III/A-IV gene cluster in familial combined hyperlipidemia: effects on LDL-cholesterol and apolipoproteins B and C-III. J Lipid Res. 1996;37:136-147.
94. Dallinga-Thie GM, van Linde-Sibenius Trip M, Rotter JI, Cantor RM, Bu X-D, Lusis AJ, de Bruin TWA. Complex genetic contribution of the apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia. J Clin Invest. 1997;99:953-961.
95. Ribalta J, La Ville AE, Vallvé JC, Humphries S, Turner PR, Masana L. A variation in the apolipoprotein C-III gene is associated with an increased number of circulating VLDL and IDL particles in familial combined hyperlipidemia. J Lipid Res. 1997;38:1061-1069.
96. Staels B, Vu-Dac N, Kosykh VA, Saladin R, Fruchart J-C, Dallongeville J, Auwerx J. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. J Clin Invest. 1995;95:705-712.
97. Hertz R, Bishara-Shieban J, Bar-Tana J. Mode of action of peroxisome proliferators as hypolipidemic drugs. J Biol Chem. 1995;270: 13470-13475.
98. Auwerx J, Schoonjans K, Fruchart J-C, Staels B. Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Atherosclerosis. 1996;124(suppl):S29-S37.
99. Knott TJ, Robertson ME, Priestly LM, Wallis S, Scott J. Characterization of mRNAs encoding the precursor for human apolipoprotein CI. Nucleic Acids Res. 1984;12:3909-3915.
100. Jackson RL, Sparrow JT, Baker HN, Morrisett J, Taunton OD, Gotto AM Jr. The primary structure of apolipoprotein-serine. J Biol Chem. 1974;249:5308-5313.
101. Shulmann RS, Herbert PN, Wehrly K, Frederickson DS. The complete amino acid sequence of C-I (apoLP-Ser), an apolipoprotein from human very low density lipoproteins. J Biol Chem. 1975;250:182-190.
102. Rozek A, Buchko GW, Cushley RJ. Conformation of two peptides corresponding to human apolipoprotein C-I residues 7-24 and 35-53 in the presence of sodium dodecyl sulfate by CD and NMR spectroscopy. Biochemistry. 1995;34:7401-7408.
103. Curry MD, McConathy WJ, Fesmire JD, Alaupovic P. Quantitative determination of apolipoproteins C-I and C-II in human plasma by separate electroimmunoassays. Clin Chem. 1981;27:543-548.
104. Sharpe CR, Sidoli A, Shelley CS, Lucero MA, Shoulders CC, Baralle FE. Human apolipoproteins AI, AII, CII and CIII, cDNA sequences and mRNA abundance. Nucleic Acids Res. 1984;12:3917-3932.
105. Jackson CL, Bruns GAP, Breslow JL. Isolation and sequence of a human apolipoprotein CII cDNA clone and its use to isolate and map to human chromosome 19 the gene for apolipoprotein CII. Proc Natl Acad Sci U S A. 1984;81:2945-2949.
106. Fojo SS, Law SW, Brewer HB Jr. Human apolipoprotein C-II: complete nucleic acid sequence of preapolipoprotein C-II. Proc Natl Acad Sci U S A. 1984;81:6354-6357.
107. Captano AL, Kinnunen PKJ, Breckenridge WC, Gotto AM Jr, Jackson RL, Little JA, Smith LC, Sparrow JT. Lipolysis of apoC-II deficient very low density lipoproteins: enhancement of lipoprotein lipase action by synthetic fragments of apoC-II. Biochem Biophys Res Commun. 1979;89:951-957.
108. Kinnunen PKJ, Jackson RL, Smith LC, Gotto AM Jr, Sparrow JT. Activation of lipoprotein lipase by native and synthetic fragments of human plasma apolipoprotein C-II. Proc Natl Acad Sci U S A. 1977;74: 4848-4851.
109. Cheng Q, Blackett P, Jackson KW, Conathy WJ, Wang C-S. C-terminal domain of apolipoprotein CII as both activator and competitive inhibitor of lipoprotein lipase. Biochem J. 1990;269:403-407.
110. Herbert PN, Assmann G, Gotto AM Jr, Frederickson DS. Disorders of the lipoprotein and lipid metabolism. In: Stanbury JB, Wyngaarden JB, Frederickson DS, Goldstein JL, Brown MS, eds. The Metabolic Basis of Inherited Diseases. 5th ed. New-York, NY: McGraw-Hill; 1983: 589-651.
111. Sparrow JT, Pownall HJ, Hsu F-J, Blumenthal LD, Culwell AR, Gotto AM. Lipid binding by fragments of apolipoprotein CIII-1 obtained by thrombin cleavage. Biochemistry. 1977;16:5427-5431.
112. Trieu VN, McConathy WJ. APOC-III-β-Galactosidase hybrid distinguishes between VLDL and LDL phospholipids. Biochem Biophys Res Commun. 1995;211:754-760.
113. Brown WB, Levy RI, Frederickson DS. Further characterization of apolipoproteins from the human plasma very low density lipoproteins. J Biol Chem. 1970;245:6588-6594.
114. Vaith P, Assmann G, Uhlenbruck G. Characterization of the oligosaccharide chain of apolipoprotein C-III from human plasma very low density lipoproteins. Biochim Biophys Acta. 1978;541:234-240.
115. 0 lacks carbohydrate residues: use of mass spectrometry to study apolipoprotein structure. J Lipid Res. 1989;30:1781-1787.
116. Nestel PJ, Fidge NH. Apoprotein C metabolism in man. Adv Lipid Res. 1982;19:55-83.
117. Bilheimer DW, Eisenberg S, Levy RI. The metabolism of very low density lipoprotein proteins, I: preliminary in vitro and in vivo observations. Biochim Biophys Acta. 1972;260:212-221.
118. Eisenberg S, Bilheimer DW, Levy RI. The metabolism of very low density lipoprotein proteins, II: studies on the transfer of apoproteins between plasma lipoproteins. Biochim Biophys Acta. 1972;280:94-104.
119. McKeone BJ, Massey JB, Knapp RD, Pownall HJ. Apolipoprotein C-I, C-II, and C-III: kinetics of association with model membranes and intermembrane transfer. Biochemistry. 1988;27:4500-4505.
120. Gibson JC, Rubinstein A, Brown WV, Ginsberg HN, Greten H, Norum R, Kayden H. ApoE-containing lipoproteins in low or high density lipoprotein deficiency. Arteriosclerosis. 1985;5:371-380.
121. Mahley RW, Innerarity TL, Rail SC Jr, Weisgraber KH. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res. 1984;25: 1277-1294.
122. Rubinstein A, Gibson JC, Paterniti JR, Kakis G Jr, Little A, Ginsberg HN, Brown WV. Effect of heparin-induced lipolysis on the distribution of apolipoprotein E among lipoprotein subclasses. J Clin Invest. 1985; 75:710-721.
123. Bukberg PR, Le N-A, Ginsberg HN, Gibson JC, Rubinstein A, Brown WV. Evidence for non-equilibrating pools of apolipoprotein C-III in plasma lipoproteins. J Lipid Res. 1985;26:1047-1057.
124. Tornoci L, Scheraldi CA, Li X, Ide H, Goldberg IJ, Le N-A. Abnormal activation of lipoprotein lipase by non-equilibrating apoC-II: further evidence for the presence of non-equilibrating pools of apolipoproteins C-II and C-III in plasma lipoproteins. J Lipid Res. 1993;34:1793-1803.
125. Zhang L-H, Kotite L, Havel RJ. Identification, characterization, cloning and expression of apolipoprotein C-IV, a novel sialoglycoprotein of rabbit plasma lipoproteins. J Biol Chem. 1996;271:1776-1783.
126. Windier E, Chao Y, Havel RJ. Determinants of hepatic uptake of triglyceride-rich lipoproteins and their remnants in the rat. J Biol Chem. 1980;255:5475-5480.
127. Windler E, Chao Y, Havel RJ. Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat. J Biol Chem. 1980;255: 8303-8307.
128. Windler EE, Kovanen PT, Chao YS, Brown MS, Havel RJ, Goldstein JL. The estradiol-stimulated lipoprotein receptor of rat liver: a binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E. J Biol Chem. 1980;255:10464-10471.
129. Windler E, Havel RJ. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res. 1985;26:556-565.
130. Shelburne F, Hanks J, Meyers W, Quarfordt S. Effect of apolipoproteins on hepatic uptake of triglyceride emulsions in the rat. J Clin Invest. 1980;65:652-658.
131. Quarfordt SH, Michalopoulos G, Schirmer B. The effect of human C apolipoproteins on the in vitro hepatic metabolism of triglyceride emulsions in the rat. J Biol Chem. 1982;257:14642-14647.
132. Kortz WJ, Schirmer BD, Mansbach CM II, Shelburne F, Toglia MR, Quarfordt SH. Hepatic uptake of chylomicrons and triglyceride emulsions in rats fed diets of differing fat content. J Lipid Res. 1984; 25:799-804.
133. Oswald B, Quarfordt S. Effect of apoE on triglyceride emulsion interaction with hepatocytes and hepatoma G2 cells. J Lipid Res. 1987;28: 798-809.
134. Kowal RC, Herz J, Weisgraber KH, Mahley RW, Brown MS, Goldstein JL. Opposing effects of apolipoprotein E and C on lipoprotein binding to the low density lipoprotein receptor-related protein. J Biol Chem. 1990;265:10771-10779.
135. Weisgraber KH, Mahley RW, Kowall RC, Herz J, Goldstein JL, Brown MS. Apolipoprotein C-I modulates the interaction of apolipoprotein E with β-migrating very low density lipoproteins (β-VLDL) and inhibits binding of β-VLDL to low density lipoprotein receptor-related protein. J Biol Chem. 1990;265:22453-22459.
136. Swaney JB, Weisgraber KH. Effect of apolipoprotein C-I peptides on the apolipoprotein E content and receptor-binding properties of β-migrating very low density lipoproteins. J Lipid Res. 1994;35: 134-142.
137. Sehayek E, Eisenberg S. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem. 1991;266:18259-18267.
138. Agnani G, Bard JM, Candelier L, Delattre S, Fruchart JC, Clavey V. Interaction of LpB, LpB:E, LpB:C-III, and LpB:C-III:E lipoproteins with the low density lipoprotein receptor of HeLa cells. Arterioscler Thromb. 1991;11:1021-1029.
139. Clavey V, Lestavel-Delattre S, Copin C, Bard JM, Fruchart JC. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII and E. Arterioscler Thromb Vasc Biol. 1995;15:963-971.
140. Jong MC, Dahlmans VEH, van Gorp PJJ, Willems van Dijk K, Koopmans S-J, Chan L, Hofker MH, Havekes LM. The binding of VLDL to the VLDL receptor is inhibited by an excess of apoC1. Circulation. 1996;94(suppl I):I-698. Abstract.
141. Mann CJ, Troussard AA, Yen FT, Hannouche N, Najib J, Fruchart J-C, Lotteau V, André P, Bihain BE. Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor. J Biol Chem. 1997;272: 31348-31354.
142. Havel RJ, Fielding CJ, Olivecrona T, Shore VG, Fielding PE, Egelrud T. Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoprotein lipase from different sources. Biochemistry. 1973;12:1828-1833.
143. LaRosa JC, Levy RI, Herbert P, Lux SE, Frederickson DS. A specific apoprotein activator for lipoprotein lipase. Biochem Biophys Res Commun. 1970;41:57-62.
144. Goldberg IJ, Scheraldi CA, Yacaoub LK, Saxena U, Bisgaier CL. Lipoprotein apoC-II activation of lipoprotein lipase. J Biol Chem. 1990; 265:4266-4272.
145. Olivecrona G, Beisiegel U. Lipid binding of apolipoprotein CII is required for stimulation of lipoprotein lipase activity against apolipoprotein CII-deficient chylomicrons. Arterioscler Thromb Vasc Biol. 1997;17:1545-1549.
146. Ekman R, Nilsson-Ehle P. Effects of apolipoproteins on lipoprotein lipase activity of human adipose tissue. Clin Chim Acta. 1975;63:29-35.
147. Brown V, Baginsky ML. Inhibition of lipoprotein lipase by an apolipoprotein of human very low density lipoprotein. Biochem Biophys Res Commun. 1972;46:375-382.
148. Krauss RM, Herbert PN, Levy RI, Frederickson DS. Further observations on the activation and inhibition of lipoprotein lipase by apolipoproteins. Circ Res. 1973;33:403-411.
149. Jackson RL, Tajima S, Yamamura T, Yokoyama S, Yamamoto A. Comparison of apolipoprotein C-II-deficient triacylglycerol-rich lipoproteins and trioleoylglycerol/phosphatidylcholine-stabilized particles as substrates for lipoprotein lipase. Biochim Biophys Acta. 1986; 875:211-219.
150. Wang C, McConathy WJ, Kloer HJ, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins: effect of apolipoprotein C-III. J Clin Invest. 1985;75:384-390.
151. McConathy WJ, Gesquiere JC, Bass H, Tartar A, Fruchart JC. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Lipid Res. 1992;33:995-1003.
152. Kinnunen PKJ, Ehnholm C. Effect of serum and C apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase. Fed Eur Biochem Soc Lett. 1976;65:354-357.
153. Landis BA, Rotolo FS, Meyers WC, Clark AB, Quarfordt SH. Influence of apolipoprotein E on soluble and heparin immobilized hepatic lipase. Am J Physiol. 1987;252(Gastrointest: Liver Physiol 15):G805-G810.
154. Soutar AK, Gamer CW, Baker HN, Sparrow JT, Jackson RL, Gotto AM Jr, Smith LC. Effect of the human plasma apolipoproteins and phosphatidylcholine acyl donor on the activity of lecithin:cholesterol acyltransferase. Biochemistry. 1975;14:3057-3064.
155. Soutar AK, Sigler GF, Smith LC, Gotto AM Jr, Sparrow JT. Lecithin: cholesterol acyltransferase activation and lipid binding by synthetic fragments of apolipoprotein C-I. Scand J Clin Lab Invest. 1978;38(suppl 150):53-58.
156. Steyrer E, Kostner GM. Activation of lecithin-cholesterol acyltransferase by apolipoprotein E: comparison of proteoliposomes containing apolipoprotein D, A-I or C-I. Biochim Biophys Acta. 1988;958: 484-491.
157. Nishida HI, Nakanishi T, Yen EA, Arai H, Yen FT, Nishada T. Nature of the enhancement of lecithin-cholesterol acyltransferase reaction by various apolipoproteins. J Biol Chem. 1986;261:12028-12035.
158. Subbaiah PV, Albers JJ, Chen CH, Bagdade JD. Low density lipoprotein-activated lysolecithin acylation by human plasma lecithin-cholesterol acyltransferase. J Biol Chem. 1980;255:9275-9280.
159. Liu M, Subbaiah PV. Activation of plasma lysolecithin acyltransferase reaction by apolipoproteins A-I, C-I and E. Biochim Biophys Acta. 1993;1168:144-152.
160. Kushwaha RS, Hasan SQ, McGill HC Jr, Getz GS, Dunham RG, Kanda P. Characterization of cholesteryl ester transfer protein inhibitor from plasma of baboons (Papio sp). J Lipid Res. 1993;34:1288-1297.
161. Sparks DL, Pritchard PH. Transfer of cholesteryl ester into high density lipoprotein by cholesteryl ester transfer protein: effect of HDL lipid and apolipoprotein content. J Lipid Res. 1989;30:1491-1498.
162. Simonet WS, Bucay N, Pitas RE, Lauer SJ, Taylor JM. Multiple tissue-specific elements control the apolipoprotein E/C-I gene locus in transgenic mice. J Biol Chem. 1991;266:8651-8654.
163. Jong MC, Dahlmans VEH, van Gorp PJJ, Breuer ML, Mol MJTM, van der Zee A, Frants RR, Hofker MH, Havekes LM. Both lipolysis and hepatic uptake of VLDL are impaired in transgenic mice coexpressing human apolipoprotein E*3Leiden and human apolipoprotein C1. Arterioscler Thromb Vasc Biol. 1996;16:934-940.
164. Shachter NS, Ebara T, Ramakrishnan R, Steiner G, Breslow JL, Ginsberg HN, Smit JD. Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein C1. J Clin Invest. 1996;98: 846-855.
165. Jong MC, Dahlmans VEH, van Gorp PJJ, Willems van Dijk K, Breuer ML, Hofker MH, Havekes LM. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway. J Clin Invest. 1996;98:2259-2267.
166. Vaisman BL, Klein H-G, Rouis M, Bérard AM, Kindt MR, Talley GD, Meyn SM, Hoyt RF, Marcovina SM, Albers JJ, Hoeg JM, Brewer HB Jr, Santamarina-Fojo S. Overexpression of human lecithin:cholesterol acyltransferase leads to hyperalphalipoproteinemia in transgenic mice. J Biol Chem. 1995;270:12269-12275.
167. Mehlum A, Staels B, Duverger N, Tailleux A, Castro G, Fievet C, Luc G, Fruchart J-C, Olivecrona G, Skretting G, Auwerx J, Pritz H. Tissue-specific expression of the human gene for lecithin:cholesterol acyl transferase alters blood lipids, lipoproteins and lipases towards a less atherogenic profile. Eur J Biochem. 1995;230:567-575.
168. Francone OL, Gong EL, Ng DS, Fielding CJ, Rubin EM. Expression of human lecithin-cholesterol acyltransferase in transgenic mice. J Clin Invest. 1995;96:1440-1448.
169. Jong MC, Gijbels MJJ, Dahlmans VEH, van Gorp PJJ, Koopmans S-J, Ponec M, Hofker MH, Havekes LM. Hyperlipidemia and cutaneous abnormalities in transgenic mice overexpressing human apolipoprotein C1. J Clin Invest. 1998;101:145-152.
170. van Ree JH, Hofker MH, van den Broek WJAA, van Deursen JMA, van der Boom H, Frants RR, Wieringa B, Havekes LM. Increased response to cholesterol feeding in apolipoprotein C1-deficient mice. Biochem J. 1995;305:905-911.
171. Jong MC, van Ree JH, Dahlmans VEH, Frants RR, Hofker MH, Havekes LM. Reduced very-low-density lipoprotein fractional catabolic rate in apolipoprotein C1-deficient mice. Biochem J. 1997;321: 445-450.
172. Shachter NS, Hayek T, Leff T, Smith JD, Rosenberg DW, Walsh A, Ramakrishnan R, Goldberg IJ, Ginsberg HN, Breslow JL. Overexpression of apolipoprotein C-II causes hypertriglyceridemia in transgenic mice. J Clin Invest. 1994;93:1683-1690.
173. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science. 1990;249:790-793.
174. de Silva HV, Lauer SJ, Wang J, Simonet WS, Weisgraber KH, Mahley RW, Taylor JM. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J Biol Chem. 1994;269:2324-2335.
175. Aalto-Setälä K, Weinstock PH, Bisgaier CL, Wu L, Smith JD, Breslow JL. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice. J Lipid Res. 1996;37:1802-1811.
176. Aalto-Setälä K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, Walsh A, Ramakrishnan R, Ginsberg HN, Breslow JL. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice: diminished very low density lipoprotein fractional catabolic rate associated with increased apoCIII and reduced apoE on the particles. J Clin Invest. 1992;90:1889-1900.
177. Jong MC, Dahlmans VEH, Hofker MH, Havekes LM. Nascent very low density lipoprotein triglyceride hydrolysis by lipoprotein lipase is inhibited by apolipoprotein E in a dose-dependent manner. Biochem J. 1997;328:745-750.
178. Ebara T, Ramakrishnan R, Steiner G, Shachter NS. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice: apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J Clin Invest. 1997;99:2672-2681.
179. Maeda N, Li H, Lee D, Oliver P, Quarfordt SH, Osada J. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem. 1994;269:23610-23616.
180. Allan CM, Taylor JM. Expression of a novel human apolipoprotein (apoC-IV) causes hypertriglyceridemia in transgenic mice. J Lipid Res. 1996;37:1510-1518.